awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q44582795-16B3CF31-31F8-45D2-8B9A-FB70BFAB5FAD
Q44582795-16B3CF31-31F8-45D2-8B9A-FB70BFAB5FAD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q44582795-16B3CF31-31F8-45D2-8B9A-FB70BFAB5FAD
Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
P2860
Q44582795-16B3CF31-31F8-45D2-8B9A-FB70BFAB5FAD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q44582795-16B3CF31-31F8-45D2-8B9A-FB70BFAB5FAD
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
41e0937eadb1f3ead657852ad0b104fe8ca40c31
P2860
Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).